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CC BY-NC-ND license (http://creativeAbstract Objective: This study investigated the regulatory effect of non-classical immune
parameters on immune thrombocytopenic purpura (ITP) mice by a spleen-invigorating, qi-re-
plenishing and blood-containing formula (SQBF).
Method: A total of 80 BALB/c mice were randomly divided into four equal groups (20 mice
each): control group, model group, prednisone group and spleen-invigorating, qi-replenishing
and blood-containing (SQBF) group. Mice in the model group, prednisone group, and SQBF
group were administered anti-platelet serum to induce ITP. The dynamic variations of platelet
counts in ITP mice were measured with an automatic blood analyzer before modeling and 48 h,
and 8, 12 and 15 days following APS injection. Levels of b-endorphin (b-EP), vasoactive intes-
tinal peptide (VIP) and salivary IgA (SIgA) were detected by enzyme-linked immunosorbent
assay (ELISA) on 15th day of experiment.
Results: SQBF enhanced peripheral blood platelet counts in ITP mice similar to that of predni-
sone, and both groups showed a statistically significant response compared with the model
group (P < .01). The SQBF significantly decreased b-EP levels compared with the model and
prednisone intervention groups (P < .05), significantly increased the levels of VIP and SIgA incom (X. Chen).
f Beijing University of Chinese Medicine.
16.02.003
f Chinese Medicine. Production and hosting by Elsevier B.V. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
92 T. Li et al.ITP mice compared with the model group (P < .05) and had significant protective effects on the
thymus of ITP mice compared with the model group (P < .01).
Conclusions: The SQBF had a similar effect to prednisone with regards to enhancing peripheral
blood platelet counts in ITP mice. Furthermore, it decreased b-EP levels and increased VIP and
SIgA, and protected the thymus. This shows that, on base of the brain-gut axis functions, some
non-classical immune vascular active factors or neurotransmitters are also involved in immune
responses, and also have relationship with the onset of ITP and bleeding and/or hemostasis. It
needs further study to determine whether a change in these active factors is related to imme-
diate hemostasis.
ª 2015 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
The pathogenesis of immune thrombocytopenic purpura
(ITP) is generally believed to be caused by abnormalities of
immune cells and humoral immunity that lead to the gen-
eration of antibodies to platelets (PAIgG, PAlgM). These
bind to platelet membrane glycoproteins, causing the
destruction of platelets in the reticuloendothelial system.
This causes a decrease in platelet numbers, a shortening of
the platelet life span and change in platelet function.1e3
Currently, adrenocortical hormones such as prednisolone,
prednisone, dexamethasone and hydrocortisone4 represent
the first-line therapy for ITP. Shortly after receiving stan-
dardized treatment, the platelet count of some ITP pa-
tients increases significantly, with a significant
improvement in bleeding tendency. However, the long-
term and repeated use of adrenocortical hormones causes
adverse drug reactions, including central obesity, hyper-
glycemia, edema, hypertension and bone necrosis.
Furthermore, hormone dependence and ineffectiveness
may also develop, reducing the clinical therapeutic effects
of adrenocortical hormones.5 Therefore, we aimed to
identify a single drug or combination of drugs from con-
ventional Chinese herbal medicine that might provide
clinical benefit to patients in the place of hormone therapy.
A prospective central randomized controlled clinical trial
(register ID: ChiCTR-TRC-13003602) reported that a spleen-
invigorating, qi-replenishing and blood-containing formula
(SQBF) might be an alternative treatment for ITP because it
had efficacy in treating chronic ITP-afflicted patients with
hormone dependence and ineffectiveness. The main ther-
apeutic effects of SQBF were symptom relief, rapidly
mitigating bleeding tendency and slowly increasing platelet
counts. This study investigated whether the therapeutic
effects of this formula were related to immune regulation.Materials
Animals
Fifty guinea pigs weighing 250 g (25 males and 25 females)
were purchased from the Tian Rui Experimental Animal
Farm in Xing Ping, Shanxi Province, China [License number:
SCXK (Shan Xi) 2012-001; common breeding environment].Eighty BALB/c mice weighting 18e22 g (40 males and 40
females) were purchased from the Laboratory Animal
Center of the Fourth Military Medical University [License
number: SCXK (Shan Xi) 2014-002; specific pathogen free
breeding].
Drugs
SQBF
SQBF consists of Radix Astragali Preparata (Radix Astragali
seu Hedysari Praeparatae), Salviae miltiorrhizae (Radix
Codonopsis pilosulae), Poria (Poria), Largehead Atractyl-
odes Rhizome (Rhizoma Atractylodis Macrocephalae),
Donkey-hide Gelatin (Colla Corii Asini) and Radix Rubiae
(Radix Rubiae), prepared and provided by Xi’an Xinghua
Drug Research Institute based on the pharmaceutical
standards for new drugs. Drug preparation: the water
extraction process was adopted, and the preparation pro-
cess was as follows: Donkey-hide Gelatin (Colla Corii Asini)
was ground into fine powder, and screened filtered through
an 80-mesh sieve. Other drugs were soaked in water over-
night, and decocted twice. First, eight cups (400 mL/cup)
of cold water were added to the herbs in SQBF except
Donkey-hide Gelatin (Colla Corii Asini) and boiled 2 h. The
liquid was strained and kept as the decoction. Then six cups
of water were added to the previously cooked herbs and
they were boiled for 2 h. The two decoctions were subse-
quently blended, condensed into a thick paste without
dregs, dried at 80C to be powder which was screened
through an 80-mesh sieve. The final medication was ob-
tained by blending this powder and Donkey-hide Gelatin
(Colla Corii Asini). Quality standards are according to the
classification and reporting requirements for Chinese
medicine, for natural medicines in the “drug registration
management method”. Radix Astragali Preparata (Radix
Astragali seu Hedysari Praeparatae) was conducted using
the thin-layer chromatography TLC identification method
and High Performance Liquid Chromatography Evaporative
Light Scattering Detector (HPLC-ELSD) methods, respec-
tively. Results of thin-layer chromatography showed that
the thin layer identification of Radix Astragali Preparata
(Radix Astragali seu Hedysari Praeparatae) was consistent
with the standards under the category of Radix Astragali
Preparata (Radix Astragali seu Hedysari Praeparatae) in the
Chinese Pharmacopoeia 2010 edition. Integral precision
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viation (RSD) of integral value of the peak area was 1.6%;
the repeatability test showed that average content of that
was 0.1224 mg/g, and the RSD was 3.14%; the sample re-
covery test showed that the average recovery rate of
astragaloside IV was 94.90% and RSD was 2.19%. The results
of three testing methods were found to be consistent with
the content standards under the Radix Astragali Preparata
(Radix Astragali seu Hedysari Praeparatae) in the Chinese
Pharmacopoeia 2010 edition.
Prednisone
Prednisone was purchased from Shanghai Jingchun Scien-
tific Co. Ltd. and dissolved in saline at a concentration of
1 mg/mL.
Reagents
Enzyme-linked immunosorbent assay (ELISA) kits for mouse
SIgA, b-EP, and VIP were purchased from the Wuhan Gene
Biotech Co. Ltd. Complete Freund’s adjuvant and incom-
plete Freund’s adjuvant were obtained from SigmaeAldrich
(St. Louis, Missouri, United States).
Apparatus
Electronic analytical balance (Satorius BSA224S, Germany);
high-speed micro-centrifuge (Chang Sha Xiang Yi H1650-W,
China); high-speed freezing centrifuge (Eppendorf 5804R,
Germany); automatic animal blood analyzer (Perlong
XFA6130, China); ultra-purified water system (Millipore
Synergy UV, Germany); remote infrared thermometer (NC-
9900, China); electronic balance; and timer.
Methods
Preparation of anti-platelet serum
Anti-coagulated whole blood from anesthetized BALB/c
mice was subject to gradient centrifugation to obtain
platelets, washed twice with phosphate buffered saline
(PBS), resuspended in PBS, and counted. The concentration
was then adjusted to 2.5  106/mL. Platelets (the antigen)
were evenly mixed with an equal amount of complete
Freund’s adjuvant or incomplete Freund’s adjuvant. Com-
plete Freund’s adjuvant plus antigen was injected at week
0 into the paws of guinea pigs, back and subcutaneous areas
(five areas), for a total injection volume of 1 mL. Incom-
plete Freund’s adjuvant plus antigen was injected into the
same areas and points at weeks 1, 2 and 4. Serum taken
from guinea pig heart was centrifuged to obtain anti-
platelet serum6 (GP-APS). GP-APS was then placed in a
water bath at 56C for 30 min to inactivate complement
and allow erythrocyte adsorption. It was diluted with saline
at a ratio of 1:4.
Measurement of GP-APS titer
Mouse platelets obtained by centrifugation were washed
three times with PBS, and the concentration was adjustedto 6  104/mL. Then, 50-mL platelet suspension was added
to microtiter wells and centrifuged for 13 min at 560 g.
Buffer (0.2% gelatin, 0.1% sodium azide, 0.05% polysorbate,
0.15 mol/L PBS) was added, incubated overnight at 4C and
washed. Next, 50-mL test serum was added and the mixture
was incubated for 1 h at 37C and washed. Then, 100-mL
enzyme-linked A protein was added, incubated for 45 min
at 22C, and washed four times. 200 mL PNPP
(C6H4NNa2O6P) solution (PNPP dissolved in diethanolamine
buffer, 1.5 mg/mL) was added and incubated for 30 min at
37C. Finally, 50-mL sodium hydroxide was added to
terminate the reaction. The optical density (OD) was
measured with a microplate reader at 405 nm wavelength.
Determination of experimental drug dose
Based on the Principle of Medical Experimental Animal
Science, the dose (mg/kg) of drug used in mice Z body
surface area conversion factor  human dose. The animal
surface area was measured by the MeeheRubner equation:
body surface area m2Z 9.1  body weight (g) 2/(3  1000).
The body surface area conversion factor for mouse to
human was 9.01. Referring to the human dosage of pred-
nisone and the SQBF, the effective dosage of prednisone
acetate was determined to be 1 mg/mL (20 times the
clinical dose) concentration in this study. The effective
dosage of the spleen-invigorating, qi-replenishing and
blood-containing formula was calculated and determined
by referring to the clinical dosage.
Modeling grouping
The number of platelets in blood taken from the tail vein of
BALB/c mice was measured by an automatic animal blood
analyzer. Eighty BALB/c mice were randomly divided into
four equal groups (20 mice each): control group, model
group, prednisone group and SQBF group. Mice in the blank
control group were given an intraperitoneal injection of
100 mL/20 g saline; mice in other groups were repeatedly
given an intraperitoneal injection of 100 mL/20 g GP-APS
daily until the end of the experiment. On the eighth day
following GP-APS injection, oral dose in mice was pro-
ceeded (0.2 mL per 10 g body weight). Mice in the blank
control group were given an intraperitoneal injection of
saline only.
Detection of peripheral blood platelets
The blood platelet count of blood from the tail vein of mice
was measured by an automatic animal blood analyzer. The
results were recorded and statistically processed. The time
points for detection were before APS injection, 48 h after
APS injection, and Days 8, 12 and 15 after starting the
administration of APS injection.
Detection of immune parameters in mouse serum
After treatment, whole blood from anesthetized mice was
centrifuged after standing. Serum was obtained. The levels
of SIgA, b-EP, and VIP were measured by ELISA according to
the manufacturer’s instructions. A standard curve was
94 T. Li et al.drawn and a regression equation was established according
to the concentration of the standard and corresponding OD
value provided in the kit. The corresponding sample con-
centration was calculated by the regression equation ac-
cording to the OD values of samples. The results were
recorded and statistically processed.
Detection of viscera indexes
Two days after the final administration of drugs, the body
weight of mice was measured. Then spleen and thymus
were removed and weighed. The viscera indexes were
calculated by the following formula: viscera
index Z weight of viscera (mg)/body weight (g).
Statistical methods
The experimental results were expressed as the
mean  standard deviation (SD) and comparisons between
groups were conducted using ANOVA. Pairwise comparisons
were conducted by t-test. The P value of 0.05 was consid-
ered statistically significant.
Results
Mouse anti-platelet serum titers
A titer assay was performed before the establishment of
the ITP mouse model. The OD value in the APS serum group
was twice that in the control group (Table 1).
Peripheral blood platelet counts
The peripheral blood platelet counts of mice in different
groups are shown in Table 2.
Data from Table 2 indicates that before APS injection,
there was no significant difference in platelet counts be-
tween the different groups (P > .05). And 48 h after APS
injection, the platelet counts of mice in the model group,
prednisone group and spleen-invigoration group were
significantly decreased compared with the control group
(P < .05). Between Day 8 and Day 12 after APS injection,
the platelet counts in the model group, prednisone group
and spleen-invigoration group were significantly decreased
(the lowest point in the study) compared with the blank
control group (P < .01). On Day 15 (the 8th Day after the
administration of prednisone) following APS injection,
platelet counts in the model group remained at a low level
(P < .01) compared with the control group while the
platelet count in the prednisone group and spleen-
invigoration group increased significantly compared with
the model group (P < .01).Table 1 OD values of the APS serum titer assay.
Grouping OD value (405 nm)
APS serum group 0.300  0.037*
Control group 0.163  0.012
Compared with the control group,*P < .05.Detection of immune parameters
The serum of mice in each group was collected after the
experiment ended. Levels of SIgA, b-EP and VIP are shown
in Table 3 and Fig. 1.
Table 3 and Fig. 1 show that b-EP was significantly
increased in the model group compared with the control
group (P < .05), but there was no difference in levels be-
tween the model control group and prednisone group
(P > .05). However, b-EP levels were significantly decreased
after intervention with SQBF. VIP levels were reduced
compared with the blank control group (P < .05), and were
significantly increased after prednisone or the SQBF
(P < .05) compared with the model group. Compared with
the blank control group, the levels of SIgA were significantly
increased after prednisone intervention or SQBF (P < .05).
Thymus and spleen indexes
At the end of the experiment, mice were weighed and their
spleen and thymus indexes calculated (Table 4, Figs. 2e4).
Table 4 and Figs. 2e4 indicate that the spleen and
thymus weights in the model group were significantly
enlarged by immune responses following APS injection
compared with the control group (P < .05). After predni-
sone intervention, the spleen and thymus were significantly
reduced in size compared with the model group (P < .01).
After intervention with SQBF, there was a significant dif-
ference in thymus size (P < .01), but not in spleen size,
compared with the model group (P > .05).Discussion
Treatment and mechanism of ITP
ITP-treatment aims to increase the platelet count in the
peripheral blood of patients to mitigate bleeding. To
promptly control bleeding and reduce the risk of death,
high-dose adrenocortical hormone, immunoglobulins and
infusion of platelets are usually employed as the first-line
therapy for patients suffering from severe bleeding or who
are at risk of severe bleeding.7 For chronic ITP patients,
maintenance treatment using adrenocortical hormones is
one of the most effective therapies. A therapeutic effect
can be achieved in some patients although complications
related to treatment need to be addressed. For those ITP
patients who develop resistance to or are dependent on
first-line therapy, second-line therapy is usually recom-
mended involving the use of the following medications:
gonadotropin inhibitors (danazol), thrombopoietin, cyclo-
sporin A, azathioprine, vincristine, vinblastine, and ritux-
imab. These are effective but induce side effects including
thrombosis, hematologic suppression, and organ
lesions.8e10 Therefore, the auxiliary or combined use of
Chinese herbal medicines might enhance the clinical ther-
apeutic effect of the medications mentioned above, and
help to relieve or reduce toxicity. In China, the treatment
of ITP by integrated therapy of both traditional Chinese
medicine and Western medicine has already become the
best therapeutic protocol available. For patients that are
Table 2 Variations of platelet counts from peripheral blood of mice (109).
APS injection time Control group Model group Prednisone group Spleen-invigoration group
Before treatment 401.17  162.54 345.50  36.46 297.00  80.95 335.17  39.15
48 h 408.00  110.39 279.33  70.69* 214.33  21.70* 156.50  95.23*
8th day 371.17  77.17 179.50  21.06: 169.83  37.99: 160.17  59.52:
12th day 436.50  60.13 183.33  10.44: 173.33  6.77: 187.00  22.08:
15th day 431.00  72.92 236.00  9.80: 360.83  93.54D 342.00  28.09D
Compared with the blank control group, *P < .05, :P < .01; compared with the model group, DP < .01. Values are the mean  SD.
Table 3 Comparison of relevant immune parameters among different groups.
Grouping Relevant immune parameters
b-EP (pg/mL) VIP (pg/mL) SIgA (mg/mL)
Control group 5.97  0.32 8.63  2.45 1.64  0.11
Model group 7.91  1.53* 5.73  2.36* 1.47  0.44*
Prednisone group 7.15  1.39 8.64  1.93D 1.96  0.31D
Spleen-invigoration group 6.23  0.62D 9.34  2.45D 2.39  0.26D
Compared with the blank control group,*P < .05; compared with the model group, DP < .05.
Values are the mean  SD.
Regulation of non-classical immune parameters 95resistant to or dependent on adrenocortical hormones or
show a poor response to second-line therapy, traditional
Chinese medicine might be a replacement therapy.11
Because the pathogenesis of ITP involves immune sys-
tem disorder, the mechanism of ITP drug action is based onFigure 1 Relevant immune pclassic T and B cells (total number of T and B cells, CD3,
CD4, CD8, natural killer cells, CD4þ CD25þ T cell pro-
portions, regulatory T cells, phagocytes, and immuno-
globulins) and the regulation of related cytokines networks
(IL-4, IL-10, interferon-g).12e14 Closely related to thearameters in each group.
Table 4 Viscera indexes of mice in each group (mg/g).
Viscera indexes Control group Model group Prednisone group Spleen-invigoration group
Spleen indexes 4.04  0.52 13.89  1.62* 9.15  1.69D 14.31  1.69*
Thymus indexes 2.73  0.49 3.62  0.70* 2.48  0.83D 2.95  0.59:
Compared with the blank control group,*P < .05; compared with the model group, :P < .05, DP < .01.
Values are the mean  SD.
96 T. Li et al.brain-gut axis functions, some non-classical immune
vascular active factors or neurotransmitters such as SIgA,
b-EP, VIP, and 5-HT are also involved in immune responses
and the onset of ITP and bleeding and/or hemostasis. This
remains an area for further study to determine whether a
change in these active factors is related to immediate
hemostasis.Relationship between non-classical immune
parameters and the onset of ITP and drug efficacy
SIgA was discovered in exocrine secretions in the early
1960s. It is mostly found in the exocrine secretions of breast
milk, gastrointestinal fluid and respiratory secretions. Pre-
vious studies confirmed that SIgA is the first line of immune
defense for the respiratory, gastrointestinal, and urogenital
tracts as protection against pathogens and hazardous
substances.15Figure 2 Spleen and thymub-EP is secreted by neurons from the pituitary, hypo-
thalamic arcuate nucleus, hippocampus and amygdala. It is
an important neuropeptide that has opiate-like effects and
regulates respiratory, circulatory and digestive functions as
well as functions of the thalamus, pituitary and adrenal
axis. Additionally, many immune cells can synthesize and
secrete b-EP as well as its receptor. b-EP also has important
physiological functions in the immune system.16
VIP is related to the occurrence, development,
outcome, treatment, and prognosis of many clinical dis-
eases. Its main function is vasodilation, information trans-
mission and immune regulation. VIP is important during
immune cell injury and/or inflammation together with pi-
tuitary adenylate cyclase activating peptide. Delgado
et al successfully treated models of multiple sclerosis
(autoimmune encephalomyelitis) and increased the number
of regulatory T cells with VIP. Pozo et al used VIP in an
in vitro culture of human CD4þ CD25 T cells, which led to
the successful induction of Foxp3þ CD4þ CD25high T cells.s indexes in each group.
Figure 3 Comparison of spleen size in each group. A: control
group, B: model group, C: prednisone group, D: spleen-
invigoration group.
Regulation of non-classical immune parameters 97Foxp3 is the key regulatory molecule for Treg cell differ-
entiation and development. VIP also plays an important role
in immune regulation.17
The non-classical immune parameters mentioned above
usually exert their immune effect in the progression of in-
fectious diseases and chronic inflammatory diseases. How-
ever, to date, there has been little basic and
pharmacodynamic research investigating whether the non-
classical immune factors are important for the onset and
treatment of ITP. In recent years, in our clinical practice of
treating ITP with Chinese medicine, we have found that
cipher prescription with the effect of invigorating spleen,
replenishing qi and containing blood remarkably relieved
the symptoms of ITP patients, mitigated bleeding tendency,
and slowly improved peripheral blood platelet counts. In
addition, SQBF as a primary or supplementary medication
was useful for ITP patients with hormone dependence or
ineffectiveness.18 Of note, its hemostatic effect is not
directly proportionate to the increase in platelets, sug-
gesting the hemostatic mechanism of SQBF may involve the
regulation of non-classical immune parameters such as
vasoactive substances and neurotransmitters.Figure 4 Comparison of the thymus size in each group.
A: control group, B: model group, C: prednisone group, D:
spleen-invigoration group.Analysis of experimental results
Before APS injection, comparisons of platelet counts among
different groups were not statistically significant (P > .05).
Forty-eight hours after APS injection, the platelet count of
mice in the model group, prednisone group and spleen-
invigoration group were significantly reduced compared
with the control group (P < .05).
In summary, SQBF enhanced peripheral blood platelet
counts in ITP mice similar to that of prednisone, decreased
b-EP and VIP levels and increased SIgA levels. It also
maintained the relative stability of immune organs such as
the spleen and thymus. Therefore, SQBF might be a
replacement therapy for ITP patients with resistance to or a
dependence on first-line and/or second-line therapy. The
SQBF is mostly composed of herbs that are used as a
pharmaceutical and edible resource, such as Radix Astragali
Preparata (Radix Astragali seu Hedysari Praeparatae),
Salviae Miltiorrhizae (Radix Codonopsis pilosulae), Donkey-
hide Gelatin (Colla Corii Asini). Therefore, its long-term
clinical use might be unlikely to lead to organ lesions or
other adverse reactions.References
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